Search Results
Showing Results for glycaemic outcomes
Coronavirus disease 2019 (COVID-19) is a life-threatening infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).1Â Diabetes mellitus is one of the most frequent comorbidities, related to hospitalization due to SARS-CoV-2 infection, as well as a risk factor for disease severity, ...
The 17th ATTD Conference (Amsterdam, 19–22 March 2025) showcased major innovations in diabetes care. The 15-day Dexcom G7 CGM proved accurate and user-friendly. The RADIANT trial showed Omnipod® 5 significantly improved glucose control over injections in type 1 diabetes. In type 2 diabetes, the 2IQP Study highlighted benefits of AID systems. Teplizumab also showed potential to enhance glycaemic stability in newly diagnosed type 1 diabetes, reinforcing the role of technology and immunotherapy in advancing diabetes management.
Women & Diabetes takes centre stage in this interview with Zeina Abou Rizk, Founder of DiaLeb. Zeina explores the unique challenges women face in diabetes care, the power of community and advocacy, and how DiaLeb’s annual panel fosters global awareness, education, and meaningful change through lived experiences and expert insights.
Dr Linda Siminerio, a leading expert in diabetes education and healthcare delivery, shares insights from her distinguished career. Inspired by her father’s type 1 diabetes diagnosis, she has dedicated her work to improving patient education and care models. She emphasizes the importance of a team-based approach and staying ahead of technological advancements. With AI and machine learning already influencing diabetes management, she urges healthcare providers to adapt and engage with these innovations. Through her contributions, Dr Siminerio continues to shape the future of diabetes care, ensuring that patients receive the education and support they need.
Article highlights There is growing clinical importance attributed to the development of metabolic dysfunction-associated steatotic liver disease in people with type 2 diabetes (T2D). Numerous international groups now advocate screening for advanced fibrosis in people with risk factors, such as ...
Article Highlights Early use of sodium–glucose co-transporter-2 inhibitors following myocardial infarction was associated with the following factors: Lower hospitalization for heart failure (odds ratio [OR]: 0.75; 95% confidence interval [CI]: 0.62–0.90; p=0.002). Similar cardiovascular deaths (OR: 1.04; 95% CI: 0.83–1.30; p=0.76). Similar all-cause mortality (OR: 1.00; 95% ...
Polycystic ovary syndrome (PCOS) is the most common endocrinopathy affecting women of reproductive age and is characterized by hyperandrogenism, anovulation and insulin resistance (IR).1Â Women with PCOS have a high risk of developing type 2 diabetes (T2D), dyslipidaemia, hypertension and ...
Very few trials in the history of medical science have altered the treatment landscape as profoundly as the UK Prospective Diabetes Study (UKPDS). Even 44 years after its inception, the trial and post-study follow-up findings continue to fascinate and enlighten the ...
Dry eye disease (DED) is known as dry eye syndrome (DES) or keratoconjunctivitis sicca. According to the Tear Film and Ocular Surface Society’s Dry Eye Workshop II (TFOS DEWS II), it constitutes a multifactorial disease of the ocular surface, ...
The prevalence of diabetes during pregnancy is rapidly increasing. In the USA alone, an estimated 1–2% of pregnant women have type 1 diabetes (T1D) or type 2 diabetes (T2D), and an additional 6–9% develop gestational diabetes.1 From 2000 to 2010, the prevalence of gestational ...
The FINE-HEART program aimed to evaluate the safety and efficacy of finerenone, a non-steroidal mineralocorticoid receptor antagonist (MRA), in key patient populations with type 2 diabetes, chronic kidney disease, and heart failure. By pooling data from three major Phase III trials—FINEARTS-HF, FIDELIO-DKD, and FIGARO-DKD—this comprehensive analysis sought to provide a clearer understanding of finerenone’s effects on cardiovascular mortality, renal outcomes, and hospitalizations for heart failure. The study also focused on subgroups based on diabetes control, offering valuable insights into its potential role in patients with coexisting conditions.
The latest clinical evidence surrounding the MiniMed 780G system focuses on expanding its access to younger children with type 1 diabetes. The hope is that by extending its use to children aged 2-6 years, its automated insulin delivery could significantly reduce the burden of diabetes management for families.
Dipeptidyl peptidase-4 (DPP-4) is a ubiquitous, multifunctional, 766-amino acid, type 2 transmembrane glycoprotein, which participates in the regulation of metabolic functions, immune and inflammatory responses, cancer growth and cell adhesion.1Â It has two forms: the first is a membrane-bound form, which ...
Tirzepatide is a first-in-class novel dual glucose-dependent insulinotropic peptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist (twincretin), formulated as a synthetic peptide containing 39 amino acids based on the native GIP.1Â Tirzepatide has a GIP receptor-binding affinity comparable with native GIP and ...
Despite the increasing body of knowledge of treatment strategies for diabetes, many patients with type 2 diabetes mellitus (T2DM) are still in a persistent state of poor glycaemia.1,2Â In clinical practice, achieving optimal glycaemic targets is challenging; the reasons are ...
Obesity defined as abnormal or excessive fat accumulation that presents a risk to health, is a chronic disease linked to metabolic co-morbidities, such as type 2 diabetes mellitus and cardiovascular disease, a reduced life expectancy, economic burden and reduced quality of ...
Acromegaly is a chronic disease caused by an excess of growth hormone (GH) and insulin-like growth factor 1 (IGF-1).1,2Â Besides facial and acral changes, systemic complications lead to decreased quality of life and survival rates.3Â The primary goal of acromegaly treatment ...
Type 2 diabetes (T2D) is one of the most common chronic noncommunicable diseases, its incidence is exponentially increasing and is one of the leading causes of morbidity and mortality worldwide.1Â As of 2021, T2D ranked among the top causes of ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
